John Mellors
Pittsburgh, PANPI 1780659441
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $88,722 of the $106,010 with a category attached, or 83.7%. Gilead accounts for 92.4% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2019 at $59,806 and has fallen 83.3% since, to $9,960 in 2025.
Across 53 payments — averaging $2000.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$98K
- Merck$8K
Across 68 payments — averaging $8487.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$577K
What the payments were for
- Consulting fees$88,72284%
- Travel & lodging$16,13715%
- Food & beverage$1,1511%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DELSTRIGO$6,525
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.